U.S. Markets open in 3 hrs 39 mins

Antisense Therapeutics Limited (ATHJF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0310.000 (0.000%)
At close: 9:30AM EDT
People also watch

Antisense Therapeutics Limited

6 - 8 Wallace Avenue
Toorak, VIC 3142
61 3 9827 8999

Full Time Employees9

Key Executives

Mr. Mark Diamond BSc, MBA, MAICDChief Exec. Officer, Managing Director and DirectorN/AN/AN/A
Mr. Phillip Allen Hains BBus(Acc), MBA, CAChief Financial Officer and Company Sec.N/AN/A58
Dr. George TachasDirector of Drug Discovery & PatentsN/AN/AN/A
Susan TurnerFin. & Admin. Mang.N/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Antisense Therapeutics Limited engages in the research, development, and commercialization of novel antisense pharmaceuticals in Australia. The company’s product pipeline comprises ATL1102, an antisense inhibitor targeting VLA-4 for the treatment of multiple sclerosis and asthma; and ATL1101, an antisense inhibitor of insulin like growth factor 1 receptor to treat prostate cancer. Its product pipeline also includes ATL1103, a second generation antisense drug to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action. The company is based in Toorak, Australia.

Corporate Governance

Antisense Therapeutics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.